HUGE FSD Pharma Inc. Stock Quote

HUGE [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | Canada

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	9.69%	Shs Outstand	40.00M	Perf Week	-2.44%
Market Cap	40.10M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	34.58M	Perf Month	-18.13%
Income	-39.00M	PEG	-	EPS next Q	-	Inst Own	1.49%	Short Float	1.03%	Perf Quarter	-15.68%
Sales	-	P/S	-	EPS this Y	58.90%	Inst Trans	-	Short Ratio	3.34	Perf Half Y	-16.74%
Book/sh	1.52	P/B	0.53	EPS next Y	-	ROA	-48.90%	Target Price	-	Perf Year	-55.56%
Cash/sh	0.74	P/C	1.08	EPS next 5Y	-	ROE	-57.00%	52W Range	0.69 - 1.94	Perf YTD	-21.57%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-58.76%	Beta	0.87
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	-	Gross Margin	-	52W Low	15.16%	ATR	0.07
Employees	10	Current Ratio	4.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	38.76	Volatility	12.84% 7.99%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	61.00%	Profit Margin	-	Rel Volume	0.41	Prev Close	0.80
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	106.95K	Price	0.80
Recom	-	SMA20	-11.75%	SMA50	-14.05%	SMA200	-27.85%	Volume	47,284	Change	-0.02%

Jun-27-22 08:30AM	FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates Business Wire
Jun-01-22 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Submission of an Investigational New Drug or IND Application with the U.S. Food and Drug Administration and Health Canada for Treatment of a Yet-To-Be-Disclosed Inflammatory Disorder GlobeNewswire
May-31-22 08:30AM	FSD Pharma Files Investigational New Drug Application ("IND") with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates Business Wire
May-24-22 08:30AM	FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs Business Wire
May-11-22 06:00AM	InvestmentPitch Media Video Discusses FSD Pharma, a Life Sciences Holding Company, and the Closing of its Sale of Non-Core Assets for $16.4 million GlobeNewswire
May-10-22 03:00AM	FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets Business Wire
May-06-22 10:41AM	FSD Pharma Announces Dismissal of Derivative Complaint Business Wire
May-02-22 03:30AM	FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates Business Wire
Apr-21-22 08:30AM	FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board Business Wire
Apr-08-22 08:30AM	FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari Business Wire
Apr-06-22 08:30AM	FSD Pharma Issues Corporate Updates Business Wire
Mar-31-22 09:30AM	FSD Pharma Announces Filing of Year-End 2021 Results Business Wire
Mar-15-22 03:30AM	FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC Business Wire -5.70%
Feb-28-22 03:10AM	InvestmentPitch Media Video Discusses FSD Pharmas, a Life Sciences Holding Company, Agreement to Sell Former Cannabis Processing Facility in Cobourg, Ontario for $16,500,000 Video Available on Investmentpitch.com GlobeNewswire
Feb-25-22 08:30AM	FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000 Business Wire +23.86%
Jan-20-22 03:30AM	FSD Pharma Announces Launch of New Corporate Website Business Wire
Jan-18-22 03:30AM	FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada Business Wire
Jan-04-22 03:30AM	FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th Business Wire
Dec-30-21 03:30AM	FSD Pharma Announces Share Repurchase Program Business Wire +5.82%
Dec-09-21 08:00AM	FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members Business Wire
Dec-03-21 08:43AM	FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th Business Wire -9.45%
03:05AM	InvestmentPitch Media Video Discusses FSD Pharma's Unveiling of Video Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Mouse Models - Video Available on Investmentpitch.com Newsfile
Dec-02-21 04:55PM	The Power Play by the Market Herald Releases New Interviews With Lumiera, Fsd Pharma, HydroGraph, and Adastra Holdings ACCESSWIRE +8.55%
08:00AM	FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models) Business Wire
Nov-16-21 08:30AM	FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish Business Wire
Oct-19-21 08:30AM	FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH Business Wire +8.45%
Oct-18-21 08:35AM	KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing PR Newswire
08:35AM	KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing CNW Group
Oct-13-21 08:00AM	FSD Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th PR Newswire
Sep-22-21 06:30PM	FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker Business Wire
03:05AM	InvestmentPitch Media Video Discusses FSD Pharma's Closing of its acquisition of Canadian Specialty Psychedelic Pharmaceutical Company Lucid Psycheceuticals - Video Available on Investmentpitch.com Newsfile
Sep-21-21 09:47AM	FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition Business Wire +7.59%
Aug-30-21 11:21AM	Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold Benzinga
Aug-26-21 11:25AM	InvestmentPitch Media Video Discusses FSD Pharma's Definitive Agreement to Acquire 100% of Lucid Psycheceuticals Inc. - Video Available on Investmentpitch.com Newsfile
Aug-25-21 01:41PM	FSD Pharma To Buy Canadian Psychedelic Pharmaceutical Firm Benzinga +6.98%
12:03PM	36 Stocks Moving In Wednesday's Mid-Day Session Benzinga
09:00AM	FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals Business Wire
07:57AM	See Why FSD Pharma Terminated COVID-19 Trial Benzinga
Aug-24-21 04:01PM	FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial Business Wire
Jul-28-21 10:05AM	InvestmentPitch Media Video Discusses FSD Pharma's Termination of its CEO, Dr. Raza Bokhari, for Cause - Video Available on Investmentpitch.com Newsfile
Jul-27-21 08:47AM	FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause Business Wire
Jun-03-21 09:00AM	FSD Pharma Inc. Appoints a New Independent Director Business Wire +15.76%
May-26-21 06:59PM	KILL FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer Business Wire
May-17-21 03:18AM	FSD Pharma Inc. Announces Results of the Annual General and Special Meeting of Shareholders Nominees of the Concerned Shareholders Elected to the Board of Directors Business Wire
May-12-21 12:49PM	FSD Management and Board Suffers Multiple Court Losses as Shareholder Meeting Approaches Newsfile
May-10-21 08:30AM	FSD Pharma Announces Investigational New Animal Drug Filing With the FDA to Treat Dogs With Enteropathy Business Wire -7.06%
May-05-21 04:23PM	FSD Pharma Announces That ISS Recommends Shareholders Vote for the Companys Nominees to the Board Using Only the BLUE Proxy Business Wire
08:30AM	FSD Pharma Announces Appointment of Interim Chief Financial Officer Business Wire
May-03-21 07:30AM	FSD Pharma Issues Important Message to Shareholders and Response to Dissident Circular Business Wire
Apr-26-21 09:04PM	Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders' Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy Newsfile +6.06%
Apr-23-21 09:00AM	FSD Pharma Files Proxy Materials and Sends Letter to Shareholders Business Wire
Apr-05-21 07:30AM	FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting PR Newswire
07:30AM	FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting CNW Group
Mar-31-21 05:00PM	FSD Pharma Commences Proceedings Against Dissident Shareholders Business Wire
Mar-16-21 09:56PM	FSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats Business Wire
Mar-08-21 07:00AM	Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Issued Shares PR Newswire
07:00AM	Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Issued Shares CNW Group
Feb-11-21 08:40AM	FSD Pharma Announces US$20M At-The-Market Offering Business Wire -20.67%
Jan-26-21 07:30PM	FSD Provides Corporate Update Business Wire
Jan-22-21 04:30PM	FSD Pharma Sets Date for Annual Meeting Business Wire
Dec-15-20 08:35AM	FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19 Business Wire
Nov-12-20 05:00PM	FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update Business Wire
Oct-29-20 07:30AM	FSD Pharma Announces Settlement of Class Action Proceeding Business Wire
Oct-21-20 07:30AM	FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering Business Wire
Oct-16-20 07:30AM	FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering Business Wire -16.41%
Oct-05-20 07:30AM	FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients Business Wire
Sep-28-20 02:30AM	FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients ACCESSWIRE
Aug-31-20 02:30AM	FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19 Business Wire
Aug-20-20 05:45AM	HUGE.CN: FSD Pharmas FSDs Phase 1 Safety and Tolerability Study of FSD201 was Successfully Completed. Pre-IND Meeting Requested for the Treatment of COVID-19 Patients Filed with FDA. Zacks Small Cap Research +10.51%
Aug-07-20 05:45PM	FSD Pharma Reports Second Quarter 2020 Financial Results Business Wire
05:45PM	FSD Pharma Reports Second Quarter 2020 Financial Results ACCESSWIRE
Aug-06-20 05:00PM	FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors Business Wire
05:00PM	FSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional Investors ACCESSWIRE
Jul-31-20 04:49PM	FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video Newsfile -14.79%
09:00AM	FSD Pharma Inc. Announces US$10 Million Registered Direct Offering ACCESSWIRE
Jul-30-20 02:30AM	FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc. Business Wire +13.90%
Jul-13-20 02:30AM	FSD Pharma Announces US$20M At-The-Market Offering Business Wire
02:30AM	FSD Pharma Announces US$20M At-The-Market Offering ACCESSWIRE
Jun-23-20 09:00AM	InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com Newsfile -7.67%
Jun-22-20 02:30AM	FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA Business Wire
Jun-09-20 11:39AM	FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors CNW Group -7.74%
05:47AM	HUGE.CN: FSD Pharma is conducting Phase 1 clinical trial of FSD-201 for inflammation and has FDA approval for a Phase 2a clinical trial design for the treatment of COVID-19 patients Zacks Small Cap Research
Jun-04-20 09:43AM	FSD Pharma Inc. Announces C$10.125 Million Private Placement CNW Group -28.96%
Jun-03-20 04:20PM	Covid Report: Small Biotech Doubles On Plans To Test A Coronavirus Drug Investor's Business Daily +138.39%
02:30AM	FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis CNW Group
02:30AM	FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis Business Wire
May-21-20 08:30AM	FSD Pharma Monetizes Non-Core Asset with Sale of Partial Equity Stake in Pharmadrug Inc. CNW Group -6.75%
08:30AM	FSD Pharma Monetizes Non-Core Asset With Sale of Partial Equity Stake in Pharmadrug Inc. Business Wire
May-14-20 05:12PM	FSD Pharma Reports First Quarter 2020 Financial Results CNW Group
Mar-23-20 09:17AM	FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario CNW Group
Mar-10-20 09:00AM	InvestmentPitch Media Video Discusses FSD Pharma's Initiation of Phase 1 In-Human Safety & Tolerability Study of Dosing Ultra Micro-PEA for Targeting CB2 Receptors at Alfred Hospital in Australia - Video Available on Investmentpitch.com Newsfile
Mar-09-20 08:30AM	FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA) CNW Group
08:30AM	FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA) Business Wire
Mar-06-20 01:14PM	FSD Pharma Inc., Worldwide License of Natural Fatty Acid, CEO Clip Video Newsfile -10.92%
Mar-04-20 02:30AM	FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday, March 6, 2020 CNW Group +11.76%
02:30AM	FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange On Friday, March 6, 2020 Business Wire

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience